Cognitive protection of incretin‐based therapies in patients with type 2 diabetes mellitus: A systematic review and meta‐analysis based on clinical studies

Author:

Chai Sanbao1ORCID,Liu Fengqi2,Yu Shuqing2,Yang Zhirong3,Sun Feng2

Affiliation:

1. Department of Endocrinology and Metabolism Peking University International Hospital Beijing China

2. Department of Epidemiology and Biostatistics, School of Public Health Peking University Health Science Center Beijing China

3. Shenzhen Institute of Advanced Technology Chinese Academy of Sciences Shenzhen China

Abstract

AbstractAims/introductionCognitive dysfunction, including mild cognitive impairment and dementia, is increasingly recognized as an important complication of type 2 diabetes mellitus. The aims of the preset study was to investigate the cognitive protection of incretin‐based therapies, including glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors, in patients with type 2 diabetes mellitus.Materials and MethodsPubMed, EMBASE, Cochrane library, Web of Science and PsycINFO were searched from the inception through 17 January 2023 for randomized controlled trials and cohort studies on the association between incretin‐based therapies and cognitive function. A total of 15 studies were finally included in our systematic review, and eight of which were incorporated into our meta‐analysis.ResultsPooled results showed that the Mini‐Mental State Examination score in incretin‐based therapy groups was increased by 1.20 compared with the control group (weighted mean difference 1.20, 95% confidence interval 0.39–2.01). The results of eight studies assessed by the Newcastle Ottawa Quality Assessment Scale and the Cochrane Collaboration's tool, and the quality of the eight studies were at a relatively high level. Egger's regression did not show significant publication bias.ConclusionsCurrent evidence shows that incretin‐based therapies might be more effective, when compared with the other hypoglycemic drugs, for cognitive improvement in patients with type 2 diabetes mellitus.

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3